{"schemaVersion":1,"language":"en","canonical":"https://cbd.bike/guides/cbd-side-effects/","question":"CBD side effects: known risks and unanswered questions","answer":"CBD can cause drowsiness, digestive symptoms, liver problems and medicine interactions. Risk depends on the formulation, exposure and individual circumstances.","author":{"type":"Organization","name":"Cryptobedrock"},"sourceReviewDate":"2026-10-19","comparison":{"introduction":"A symptom diary, a blood test and a clinical diagnosis answer different questions. Keeping them separate makes safety information easier to use.","columns":["Observation","What it tells you","What it does not settle"],"rows":[["A person reports no symptoms","No symptoms were noticed or reported.","Whether a laboratory value changed."],["A liver enzyme exceeds a study threshold","The predefined laboratory endpoint occurred.","A diagnosis for everyone using a retail product."],["Healthy adults in a short trial","Evidence about that population and study period.","Pregnancy, existing liver disease or long-term use."],["A product has a clean contaminant report","The listed contaminants met the reported criteria.","The effects of CBD itself or a medicine combination."]]},"interpretationScope":"A short monitored study does not determine the risk of every formulation, person or duration of use.","nextStep":"Bring a dated product list, relevant medical history and any symptom timeline to the clinician assessing your situation.","sources":[{"title":"CDC · About CBD","url":"https://www.cdc.gov/cannabis/about/about-cbd.html"},{"title":"FDA · Randomized CBD liver safety trial","url":"https://www.fda.gov/drugs/regulatory-science-action/cder-investigators-address-safety-cbd-randomized-trial"},{"title":"FDA · Cannabis, CBD, pregnancy and breastfeeding","url":"https://www.fda.gov/consumers/consumer-updates/what-you-should-know-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding"},{"title":"FDA · Randomized CBD liver-safety trial","url":"https://www.fda.gov/drugs/regulatory-science-action/cder-investigators-address-safety-cbd-randomized-trial"},{"title":"FDA · CBD, pregnancy and breastfeeding","url":"https://www.fda.gov/consumers/consumer-updates/what-you-should-know-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding"}],"sourceData":{"title":"A laboratory signal can appear without noticeable symptoms","caption":"In the 28-day FDA trial, eight CBD recipients crossed the ALT/AST threshold. The reported Kaplan–Meier estimate was 5.6% (95% CI 1.8–9.3%), compared with 0% (0–7.6%) for placebo. Numbers at risk at week four were 141 and 47.","columns":["Group","Estimate and 95% CI","Events / number at risk at week 4"],"rows":[["CBD solution","5.6% (1.8–9.3%)","8 / 141"],["Placebo","0% (0–7.6%)","0 / 47"]],"scope":"The study randomized 201 healthy adults and studied an oral CBD solution at 250–550 mg/day. This is the study exposure, not a use recommendation. The result is a liver-enzyme endpoint, not the rate of symptomatic liver failure or a prediction for every retail product.","sourceUrl":"https://www.fda.gov/drugs/regulatory-science-action/cder-investigators-address-safety-cbd-randomized-trial"}}